{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T23:23:38Z","timestamp":1793229818889,"version":"4.5.0"},"reference-count":17,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2020,2,18]],"date-time":"2020-02-18T00:00:00Z","timestamp":1581984000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015542","name":"GlaxoSmithKline K.K.","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100015542","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Toxins"],"abstract":"<jats:p>In many countries, 400 units (U) is the maximum dose of onabotulinumtoxinA available to treat upper limb spasticity, but few studies have demonstrated the optimal use of this dose. In the double-blind phase of this randomized, controlled trial, we compared the efficacy and safety of 400 vs. 240 U onabotulinumtoxinA in patients with post-stroke upper limb spasticity. Both groups received 240 U onabotulinumtoxinA injected in the forearm. An additional 160 U onabotulinumtoxinA (400 U group) or placebo (240 U group) was injected in the elbow flexors. Both groups showed similar muscle tone reduction in the wrist, fingers, and thumb; muscle tone reduction in the elbow flexors was greater in the group treated with onabotulinumtoxinA (400 U group) compared to placebo (240 U group). Functional disabilities improved in both groups. No substantial difference was found in safety profiles. In the subsequent open-label phase, all participants received repeat injections of 400 U onabotulinumtoxinA (target muscles and doses per muscle determined by the physician). Similar efficacy and safety outcomes, as with the 400 U group in the double-blind phase, were confirmed. This final report demonstrates that injection of onabotulinumtoxinA 400 U relieves muscle tone in a wide range of areas and improves functional disabilities; generally, it was well-tolerated, and no new safety concerns were identified. The dosing data in the open-label phase will inform optimal use of onabotulinumtoxinA in clinical practice (ClinicalTrials.gov: NCT03261167).<\/jats:p>","DOI":"10.3390\/toxins12020127","type":"journal-article","created":{"date-parts":[[2020,2,26]],"date-time":"2020-02-26T04:18:29Z","timestamp":1582690709000},"page":"127","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Efficacy and Safety of OnabotulinumtoxinA 400 Units in Patients with Post-Stroke Upper Limb Spasticity: Final Report of a Randomized, Double-Blind, Placebo-Controlled Trial with an Open-Label Extension Phase"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6701-4974","authenticated-orcid":false,"given":"Masahiro","family":"Abo","sequence":"first","affiliation":[{"name":"Department of Rehabilitation Medicine, The Jikei University School of Medicine, Tokyo 105-8461, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Shigematsu","sequence":"additional","affiliation":[{"name":"Department of Rehabilitation Medicine, Seirei Hamamatsu City Rehabilitation Hospital, Shizuoka 433-8511, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyoshi","family":"Hara","sequence":"additional","affiliation":[{"name":"Department of Rehabilitation Medicine, Kikyogahara Hospital, Nagano 399-6461, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuko","family":"Matsuda","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline K.K., Tokyo 107-0052, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akinori","family":"Nimura","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline K.K., Tokyo 107-0052, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiyuki","family":"Yamashita","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline K.K., Tokyo 107-0052, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaoru","family":"Takahashi","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline K.K., Tokyo 107-0052, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,2,18]]},"reference":[{"key":"ref_1","unstructured":"Feldman, R.G., Young, R.R., and Koella, W.P. (1980). Symposium synopsis. Spasticity: Disordered Motor Control, Year Book Medical Publishers."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.pmrj.2011.10.001","article-title":"Relationship between disability and health-related quality of life and caregiver burden in patients with upper limb poststroke spasticity","volume":"4","author":"Doan","year":"2012","journal-title":"PM R"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1468-1331.2010.03125.x","article-title":"International consensus statement for the use of botulinum toxin treatment in adults and children with neurological impairments: Introduction","volume":"17","author":"Esquenazi","year":"2010","journal-title":"Eur. J. Neurol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/j.1468-1331.2010.03129.x","article-title":"Botulinum toxin assessment, intervention and after-care for upper limb hypertonicity in adults: International consensus statement","volume":"17","author":"Sheean","year":"2010","journal-title":"Eur. J. Neurol."},{"key":"ref_5","first-page":"227","article-title":"Botulinum toxin type A products are not interchangeable: A review of the evidence","volume":"8","author":"Brin","year":"2014","journal-title":"Biologics"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1185\/03007995.2010.497103","article-title":"Botulinum toxin type A in post-stroke upper limb spasticity","volume":"26","author":"Kaji","year":"2010","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1097\/PHM.0b013e318116090c","article-title":"Associated reaction and spasticity among patients with stroke","volume":"86","author":"Honaga","year":"2007","journal-title":"Am. J. Phys. Med. Rehabil."},{"key":"ref_8","first-page":"521","article-title":"Spasticity treatment with onabotulinumtoxin A: Data from a prospective German real-life patient registry","volume":"121","author":"Schramm","year":"2014","journal-title":"J. Neural Transm."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e002771","DOI":"10.1136\/bmjopen-2013-002771","article-title":"Results from the Upper Limb International Spasticity Study-II (ULIS-II): A large, international, prospective cohort study investigating practice and goal attainment following treatment with botulinum toxin A in real-life clinical management","volume":"3","author":"Fheodoroff","year":"2013","journal-title":"BMJ Open"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/joa.12538","article-title":"Successive motor nerve blocks to identify the muscles causing a spasticity pattern: Example of the arm flexion pattern","volume":"230","author":"Genet","year":"2017","journal-title":"J. Anat."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1080\/08990220.2018.1530651","article-title":"Assessment of post-stroke elbow flexor spasticity in different forearm positions","volume":"35","author":"Bayram","year":"2018","journal-title":"Somatosens. Mot. Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1053\/apmr.2002.35474","article-title":"Inter- and intrarater reliability of the Ashworth Scale and the Disability Assessment Scale in patients with upper-limb poststroke spasticity","volume":"83","author":"Brashear","year":"2002","journal-title":"Arch. Phys. Med. Rehabil."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/PHM.0b013e318168d36c","article-title":"Influence of botulinum toxin type A treatment of elbow flexor spasticity on hemiparetic gait","volume":"87","author":"Esquenazi","year":"2008","journal-title":"Am. J. Phys. Med. Rehabil."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1002\/mds.20499","article-title":"Association between botulinum toxin injection into the arm and changes in gait in adults after stroke","volume":"20","author":"Hirsch","year":"2005","journal-title":"Mov. Disord."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"S208","DOI":"10.1002\/(SICI)1097-4598(1997)6+<208::AID-MUS15>3.0.CO;2-1","article-title":"Dosing, administration, and a treatment algorithm for use of botulinum toxin A for adult-onset spasticity","volume":"20","author":"Brin","year":"1997","journal-title":"Muscle Nerve"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1093\/ptj\/67.2.206","article-title":"Interrater reliability of a modified Ashworth scale of muscle spasticity","volume":"67","author":"Bohannon","year":"1987","journal-title":"Phys. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"P3.027","DOI":"10.1212\/WNL.88.16_supplement.P3.027","article-title":"Safety and efficacy of high-dose onabotulinumtoxinA for post-stroke upper limb spasticity: Results of a double-blind, placebo-controlled trial","volume":"88","author":"Patel","year":"2017","journal-title":"Neurology"}],"container-title":["Toxins"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6651\/12\/2\/127\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T08:58:45Z","timestamp":1760173125000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6651\/12\/2\/127"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,18]]},"references-count":17,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,2]]}},"alternative-id":["toxins12020127"],"URL":"https:\/\/doi.org\/10.3390\/toxins12020127","relation":{},"ISSN":["2072-6651"],"issn-type":[{"value":"2072-6651","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,18]]}}}